Treatment options in first-line metastatic kidney cancer
Over the past 10 years or so, the use of [...]
Comparison of cabozantinib with axitinib as second-line treatment for metastatic kidney cancer
To date, there have not been any studies that have [...]
Lenvatinib plus everolimus for patients with metastatic kidney cancer
The treatment of heavily pretreated patients with metastatic kidney cancer [...]
Immunotherapy combinations versus TKIs for papillary renal cell carcinoma
Papillary renal cell carcinoma (pRCC) is the most common subtype [...]
Real world data on the use of cabozantinib plus immunotherapy in the second line
A recent study looked at the use of a combination [...]
Immunotherapy improves survival in kidney cancer patients with brain metastases
A recent real world study has found that giving immunotherapy [...]
Radiotherapy for the management of renal medullary carcinoma
Renal medullary carcinoma (RMC) is a rare and aggressive cancer [...]
NICE approves cabozantinib plus nivolumab for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has approved the [...]
PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
Summary of kidney cancer highlights from ASCO GU 2024
This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]
